NCT05498701View on ClinicalTrials.gov

A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 29, 2022

Primary Completion Date

December 18, 2022

Study Completion Date

December 19, 2022

Conditions
Healthy
Interventions
DRUG

Tafamidis free acid tablet (Test)

12.2 mg tafamidis free acid tablet (Test)

DRUG

Tafamidis meglumine capsule (Reference)

Commercial 20 mg tafamidis meglumine capsule (Reference)

Trial Locations (1)

M1S 3V6

Pharma Medica Research Inc, Toronto

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05498701 - A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food | Biotech Hunter | Biotech Hunter